Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | CASP2 | P42575 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KDM5C | P41229 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 3/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22214508 | 0.89 | CASP2 (0.40) | ALDH1A1NAAACASP2TSHRFAAH | |
| SCHEMBL25863483 | 0.85 | ALDH1A1 (0.39) | ALDH1A1NAAACASP2TSHRFAAH | |
| SCHEMBL12251414 | 0.84 | DNM1 (0.36) | ALDH1A1CASP2FAAHGAA | |
| SCHEMBL20623023 | 0.82 | ALDH1A1 (0.38) | ALDH1A1NAAACASP2TSHRFAAH | |
| SCHEMBL20794399 | 0.82 | GAA (0.46) | ALDH1A1NAAAFAAHKMT2AMEN1 | |
| SCHEMBL8960703 | 0.80 | KDM4A (0.36) | ALDH1A1NAAACASP2KDM4ETSHR | |
| SCHEMBL18588478 | 0.79 | ALDH1A1 (0.44) | ALDH1A1NAAACASP2TSHR | |
| SCHEMBL5030896 | 0.79 | PHF8 (0.54) | ALDH1A1NAAAKDM4EKDM5CEGLN1 | |
| SCHEMBL16281002 | 0.79 | ALDH1A1 (0.45) | ALDH1A1NAAACASP2KDM4EKDM5C | |
| SCHEMBL14002750 | 0.78 | ALDH1A1 (0.48) | ALDH1A1NAAACASP2KDM4EKDM5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11564974-B2 | Combination therapy with controlled-release CNP agonists | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2023-01-31 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| US-20220409700-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2022-12-29 | — | — | US | disclosed |
| US-20220211817-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2022-07-07 | — | — | US | disclosed |
| US-11311604-B2 | Controlled-release CNP agonists with low NPR-C binding | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2022-04-26 | — | — | US | disclosed |
| US-20220118053-A1 | Dry Pharmaceutical Formulations of CNP Conjugates | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2022-04-21 | — | — | US | disclosed |
| US-11224661-B2 | Controlled-release CNP agonists with increased NEP stability | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3922267-A1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2021-12-15 | — | — | EP | disclosed |
| US-20210369848-A1 | Conjugation Method for Carrier-Linked Prodrugs | Ascendls Pharma A/S (DK) | 2021-12-02 | — | — | US | disclosed |
| US-20190328840-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW INITIAL NPR-B ACTIVITY | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-10-31 | — | — | US | disclosed |
| US-20190328841-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-10-31 | — | — | US | disclosed |
| US-20190255183-A1 | CNP PRODRUGS | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-08-22 | — | — | US | disclosed |
| US-20190022237-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH INCREASED NEP STABILITY | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-01-24 | — | — | US | disclosed |
| US-20190015481-A1 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-01-17 | — | — | US | disclosed |
| US-20190000926-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-01-03 | — | — | US | disclosed |
| US-20180185452-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2018-07-05 | — | — | US | disclosed |
| US-9919033-B2 | Dry growth hormone composition transiently linked to a polymer carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2018-03-20 | — | — | US | disclosed |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | ASCENDIS PHARMA A/S (DK) | 2017-04-13 | — | — | US | disclosed |
| US-20170056477-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409700-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS | CNP, NPR1, NTSR2 | ALDH1A1 3352/4885NAAA 500/4885CASP2 3770/4885 |
| US-20190255183-A1 | CNP PRODRUGS | NPPA, NPR1, NPR3 | ALDH1A1 2309/4885NAAA 40/4885CASP2 1544/4885 |
| US-20210369848-A1 | Conjugation Method for Carrier-Linked Prodrugs | UGT2B7, SLC10A1, UGT1A6 | ALDH1A1 379/4885NAAA 13/4885CASP2 1772/4885 |
| US-20190328840-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW INITIAL NPR-B ACTIVITY | NPR1, NPR3, CNP | ALDH1A1 4718/4885NAAA 325/4885CASP2 1767/4885 |
| US-20170056477-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | GHRHR, GHSR, GCG | ALDH1A1 4509/4885NAAA 2137/4885CASP2 3390/4885 |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | H1-0, H1-3, H1-2 | ALDH1A1 140/4885NAAA 145/4885CASP2 2622/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | ALDH1A1 1053/4885NAAA 709/4885CASP2 1822/4885 |
| US-20190022237-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH INCREASED NEP STABILITY | CNP, NPR1, NPPA | ALDH1A1 3005/4885NAAA 181/4885CASP2 3986/4885 |
| US-20190000926-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | NPR1, NPR3, NPSR1 | ALDH1A1 4614/4885NAAA 702/4885CASP2 2946/4885 |
| US-20220211817-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | NPR1, NPR3, NPSR1 | ALDH1A1 4614/4885NAAA 702/4885CASP2 2946/4885 |
| US-11311604-B2 | Controlled-release CNP agonists with low NPR-C binding | NPR1, NPR3, NPSR1 | ALDH1A1 4614/4885NAAA 702/4885CASP2 2946/4885 |
| US-20190328841-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS | CNP, NPR1, NTSR2 | ALDH1A1 3352/4885NAAA 500/4885CASP2 3770/4885 |
| US-11224661-B2 | Controlled-release CNP agonists with increased NEP stability | CNP, NPR1, NPPA | ALDH1A1 3005/4885NAAA 181/4885CASP2 3986/4885 |
| US-20220118053-A1 | Dry Pharmaceutical Formulations of CNP Conjugates | CNP, PTMS, NPPA | ALDH1A1 1190/4885NAAA 142/4885CASP2 3818/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | ALDH1A1 1053/4885NAAA 709/4885CASP2 1822/4885 |
| US-11564974-B2 | Combination therapy with controlled-release CNP agonists | CNP, NPR1, NGF | ALDH1A1 3630/4885NAAA 1035/4885CASP2 3674/4885 |
| US-20180185452-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | GHRHR, GHSR, GCG | ALDH1A1 4509/4885NAAA 2137/4885CASP2 3390/4885 |
| US-20190015481-A1 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES | CNP, LNPEP, CSGALNACT1 | ALDH1A1 309/4885NAAA 188/4885CASP2 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.